论文部分内容阅读
目的:拟通过比较梗阻(OA)和非梗阻性无精子(NOA)症患者精液细胞DNA倍体分析与细胞学检查结果的特点,以期建立一种无创的诊疗方案以鉴别OA与NOA。方法:NOA患者20例和OA患者10例,按照WHO方法进行精液分析诊断,获取其精液标本,液化后离心取沉淀物,1份采用体积分数70%冰乙醇重悬精液沉淀,4℃固定后用PI染色,采用流式细胞仪进行DNA倍体分析。同时,取另1份精液沉淀涂片,进行Diff-Quick染色和免疫细胞化学染色。结果:DNA倍体分析结果表明,20例NOA患者精液中均存在单倍体(1N)、二倍体(2N)和四倍体(4N)细胞,其中2N细胞含量最高,约占71.25±8.73%。1N细胞的百分比含量为5.46±2.93%,4N细胞含量为3.28±2.54%。10例OA患者精液中有8例只存在2N细胞,含量为71.67±13.09%,未检测到1N和4N,2例未检测到各种倍体细胞。精液细胞学检查结果表明,20例NOA患者中有15例患者精液中可检测出生精细胞,5例患者精液中未检出生精细胞。10例OA患者精液中均未检出生精细胞,其中2例没有任何细胞。结论:精液细胞DNA倍体分析与细胞学检查作为2种无创的检查方法,均可作为评估患者生精功能的辅助诊疗手段,两者结合可作为鉴别OA和NOA的辅助诊断指标。
Objective: To compare the characteristics of DNA ploidy analysis and cytology of semen cells in patients with obstructive (OA) and non-obstructive azoospermia (NOA) to establish a non-invasive diagnosis and treatment program to identify OA and NOA. Methods: Twenty patients with NOA and 10 patients with OA were enrolled in this study. According to the WHO method, semen samples were obtained and semen samples were obtained after centrifugation by centrifugation. One pellet was resuspended with 70% PI staining, flow cytometry DNA ploid analysis. At the same time, take another sperm sediment smear, Diff-Quick staining and immunocytochemical staining. Results: DNA ploidy analysis showed that all the 20 NOA semen contained haploid (1N), diploid (2N) and tetraploid (4N) cells, with the highest content of 2N cells, accounting for 71.25 ± 8.73 %. The percentage of 1N cells was 5.46 ± 2.93% and the content of 4N cells was 3.28 ± 2.54%. There were only 2N cells in 8 cases of semen in 10 patients with OA, the content was 71.67 ± 13.09%, 1N and 4N were not detected, and 2 kinds of ploidy cells were not detected. Semen cytology results showed that spermatogenic cells were detected in 15 of 20 patients with NOA and spermatogenic cells in 5 patients. No spermatogenic cells were detected in semen of 10 patients with OA, of which 2 did not have any cells. CONCLUSIONS: DNA ploidy analysis and cytology of semen cells, as two noninvasive methods, can be used as adjuvant therapy to evaluate spermatogenic function in patients. The combination of the two can be used as an auxiliary diagnostic index to differentiate OA from NOA.